$31.47
Moderna


Performance
Dividends
1W
1M
YTD
1Y
3Y
6/36
Growth
Score
8/36
Dividend
Score
Valuation
PE Ratio
-3.63
PS Ratio
3.87
RSI
-
PEG Ratio
-0.52
PRG Ratio
-0.12
0
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
Rule
of 40
16.58%
Gross Margin
52.55%
3
Current Ratio
4.22
Return on Assets
-26.42%
0
Return on Equity
-30.1%
0
Return on inv. Capital
-33.11%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 3.24B
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -3.56B
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 1.77B
2018
2019
2020
2021
2022
2023
2024
6
Events

MRNA
Moderna
in 283 days
before market open
Earnings per Share is expected with - and revenue with - .

MRNA
Moderna
in 207 days
before market open
Earnings per Share is expected with - and revenue with - .

MRNA
Moderna
in 108 days
before market open
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
07.12.2018
MaketCap
12.22B
Country
US
CEO
Stephane Bancel
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Updated 15.07.2025